Form 4: NewAmsterdam Pharma CEO Sells Shares, Transfers to Trust

NewAmsterdam Pharma CEO Michael H. Davidson exercised options and sold 306,293 ordinary shares, also transferring 285,715 shares to a Grantor Retained Annuity Trust.

Summary

• Michael H. Davidson, CEO and Director of NewAmsterdam Pharma Co N.V., engaged in a series of transactions involving the company's ordinary shares between February 24 and February 26, 2026.
• He exercised options to acquire a total of 306,293 ordinary shares at an exercise price of EUR 1.16392 per share.
• Concurrently, he sold all 306,293 ordinary shares acquired through option exercises in the open market.
• The sales occurred at weighted average prices ranging from $33.63 to $36.68 per share.
• On February 26, 2026, Davidson transferred 285,715 ordinary shares to the Michael H. Davidson 2026 Grantor Retained Annuity Trust (GRAT), an estate planning vehicle where he is the sole annuitant and trustee.
• These transactions were conducted under a Rule 10b5-1(c) plan.
• Following these transactions, Davidson's direct beneficial ownership of ordinary shares decreased to 174,144, while his indirect beneficial ownership through the GRAT is 285,715 ordinary shares.
• The number of derivative securities (options) beneficially owned decreased from 924,559 to 682,974.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal due to the substantial insider sales and reduction in direct beneficial ownership, which could be interpreted as the CEO diversifying holdings or believing the stock is well-valued, despite the transactions being pre-planned.

Positives

• The CEO exercised a significant number of options (306,293 shares), indicating value in the underlying equity at the exercise price of EUR 1.16392.
• Shares were sold at relatively high prices, ranging from $33.63 to $36.68, suggesting a favorable market valuation at the time of sale.
• The transactions were conducted under a Rule 10b5-1(c) plan, which indicates pre-planned sales and can mitigate concerns about opportunistic timing.

Negatives

• The CEO sold all shares acquired through option exercises (306,293 shares), representing a significant reduction in his direct equity holdings from these specific transactions.
• The transfer of 285,715 shares to a GRAT, while an estate planning tool, removes these shares from his direct, immediate control and could be perceived as a reduction in personal exposure to the company's direct performance.
• The overall direct beneficial ownership of ordinary shares decreased from 524,567 (after the first option exercise on 02/24) to 174,144 (after all transactions on 02/26 and GRAT transfer).

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, even when pre-planned under a Rule 10b5-1 plan, are often scrutinized by the market for potential signals regarding management's confidence in the company's near-term prospects. In the biopharma sector, such transactions can sometimes precede or follow significant clinical trial results or regulatory milestones, making the timing of these pre-planned sales a point of interest for investors.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of Grantor Retained Annuity Trusts (GRATs) for estate planning is a common practice among high-net-worth executives, particularly in industries with volatile equity values like biopharma.
• While the specific sale prices are company-specific, the general strategy of exercising options and selling shares, often to fund tax obligations or diversify holdings, aligns with typical executive compensation and wealth management practices across various industries.
• There are no specific comparable companies or projects mentioned in the filing to provide a direct comparison of results.

Related Party Transactions

• Transfer of 285,715 ordinary shares from Michael H. Davidson to the Michael H. Davidson 2026 Grantor Retained Annuity Trust (GRAT), where he is the sole annuitant and trustee.

Stakeholder Impact

• Shareholders: May interpret the significant insider sales as a signal of management's view on the stock's valuation, potentially leading to negative sentiment or increased selling pressure. The pre-planned nature (10b5-1) might mitigate some concerns.

Key Dates

Recommendation

While the CEO's significant sales and reduction in direct ownership could be a cause for concern, the transactions were executed under a Rule 10b5-1 plan, suggesting they were pre-scheduled rather than reactive to immediate negative news. The sales occurred at favorable prices. Investors should monitor future company performance and other insider activity, but this filing alone does not warrant a strong 'sell' given the pre-planned nature and the CEO's continued indirect ownership through the GRAT and remaining options. A 'hold' position is prudent to assess further developments.

Keywords

NewAmsterdam Pharma, NAMS, Insider Trading, Form 4, Stock Sales, Option Exercise, CEO, Michael H. Davidson, Rule 10b5-1, Grantor Retained Annuity Trust, GRAT, Biopharma, Pharmaceuticals